Modified Nanoprecipitation Method for Preparation of Cytarabine-Loaded PLGA Nanoparticles

被引:0
作者
Khushwant S. Yadav
Krutika K. Sawant
机构
[1] The Maharaja Sayajirao University of Baroda,Pharmacy Department, TIFAC
[2] The Maharaja Sayajirao University of Baroda,Centre of Relevance and Excellence in NDDS
来源
AAPS PharmSciTech | 2010年 / 11卷
关键词
cytarabine; factorial design; modified nanoprecipitation method; nanoparticles; PLGA; stability studies;
D O I
暂无
中图分类号
学科分类号
摘要
The present investigation was aimed at developing cytarabine-loaded poly(lactide-coglycolide) (PLGA)-based biodegradable nanoparticles by a modified nanoprecipitation which would have sustained release of the drug. Nine batches were prepared as per 32 factorial design to optimize volume of the co-solvent (0.22–0.37 ml) and volume of non-solvent (1.7–3.0 ml). A second 32 factorial design was used for optimization of drug: polymer ratio (1:5) and stirring time (30 min) based on the two responses, mean particle size (125 ± 2.5 nm), and percentage entrapment efficiency (21.8 ± 2.0%) of the Cyt-PLGA nanoparticles. Optimized formulation showed a zeta potential of −29.7 mV indicating good stability; 50% w/w of sucrose in Cyt-PLGA NP was added successfully as cryoprotectant during lyophilization for freeze-dried NPs and showed good dispersibility with minimum increase in their mean particle sizes. The DSC thermograms concluded that in the prepared PLGA NP, the drug was present in the amorphous phase and may have been homogeneously dispersed in the PLGA matrix. In vitro drug release from the pure drug was complete within 2 h, but was sustained up to 24 h from PLGA nanoparticles with Fickian diffusion. Stability studies showed that the developed PLGA NPs should be stored in the freeze-dried state at 2–8°C where they would remain stable in terms of both mean particle size and drug content for 2 months.
引用
收藏
页码:1456 / 1465
页数:9
相关论文
共 97 条
[1]  
Ho DHW(1971)Clinical pharmacology of 1-B-D arabinofuranosylcytosine Clin Pharmacol Ther 12 944-954
[2]  
Frei E(1993)Clinical pharmacokinetics and pharmacodynamics of anticancer agents in pediatric patients Anticancer Res 13 1795-1808
[3]  
Knoester PD(1998)Slow releasing of ara-C from poly(2-hydroxyethyl methacrylate) and poly(2-hydroxyethyl methacrylate-co-N-vinyl-2-pyrrolidone) hydrogels implanted subcutaneously in the back of rats Biomaterials 19 861-869
[4]  
Underberg WJM(2000)Nonionic surfactant vesicles (Niosomes) of cytarabine hydrochloride for effective treatment of leukemias: encapsulation, storage, and Drug Dev Ind Pharm 26 217-222
[5]  
Beijnen JH(2004) release AAPS PharmSciTech 5 1-9
[6]  
Blanco MD(2004)Artificial neural network as an alternative to multiple regression analysis in optimizing formulation parameters of cytarabine liposomes Macromol Chem Phys 205 1955-1964
[7]  
Trigo RM(2004)Preparation of polymeric nanoparticles by photo-crosslinking of an acryloylated polyaspartamide in w/o microemulsion Eur J Pharm Biopharm 57 225-233
[8]  
Teijón C(1979)Cytarabine release from comatrices of albumin microspheres in a poly(lactide–co- glycolide) film: Polymer 20 1459-1464
[9]  
Gómez C(1997) and Adv Drug Deliv Rev 28 5-24
[10]  
Teijón JM(1999) studies Drug Dev Ind Pharm 25 471-476